Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Hardman & Co Life Sciences Research: Long-term cost and EBIT analysis of the pharmaceutical industry: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=download2_file&code_str=76e2f0335d941bedb39fe6be92218959
Hardman & Co Life Sciences Research: Long-term cost and EBIT analysis of the pharmaceutical industry
Hardman & Co Life Sciences Research: Long-term cost and EBIT analysis of the pharmaceutical industry
Abbvie Inc - Technical Analysis: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23878/Abbvie_logo.png
Abbvie Inc - Technical Analysis
Considering both the recent stock trend and the indicators signs combined with the fundamental analysis, Abbvie company tends to remain in hold position with a little growth in price. AbbVie Inc
Survey: International Nurses on the Front Lines of COVID-19 Care: https://mms.businesswire.com/media/20201201005032/en/841855/5/AMN-Logo.jpg
Survey: International Nurses on the Front Lines of COVID-19 Care


Nearly 90% of international nurses providing care in the United States have treated COVID-19 patients, while 17% have themselves contracted the coronavirus, according to a new survey.



Conducted

Dexcom Announces Upcoming Conference Presentation: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:




  • Jereme Sylvain, Executive Vice President and Chief

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Bob Smith, Vice President, Pfizer Rare Disease, at the 4th Annual Evercore ISI

Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) issued a Patent Term Extension Certificate for U.S. Patent

Agilent to Present at Evercore ISI Virtual Healthcare ConferencePexels:
Agilent to Present at Evercore ISI Virtual Healthcare Conference


Agilent Technologies Inc. (NYSE: A) today announced the company’s presentation at the Evercore ISI Virtual Healthcare Conference will be made available by webcast. The details:



Evercore ISI

Novocure to Participate in Two Upcoming Investor Conferences: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Participate in Two Upcoming Investor Conferences


Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences.



William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial

Agilent Reports Fourth-Quarter and Fiscal Year 2021 Financial Resultshttps://www.cyansecurity.com/:
Agilent Reports Fourth-Quarter and Fiscal Year 2021 Financial Results


Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.66 billion for the fourth quarter ended Oct. 31, 2021, up 12% year over year (core(1) growth of 11%). Revenue for the full year was

Humana Expands Value-Based Agreement with Hutchinson Clinic to Increase Medicare Advantage Access in Central Kansas: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Expands Value-Based Agreement with Hutchinson Clinic to Increase Medicare Advantage Access in Central Kansas


Humana Inc. (NYSE: HUM), a leading health and wellness company, has expanded its value-based care agreement with Hutchinson Clinic, a physician specialty group with a 60-year legacy of focusing on

Humana Announces Value-Based Agreement with Allina Health in Minnesota: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Announces Value-Based Agreement with Allina Health in Minnesota


Humana Inc. (NYSE: HUM), a leading health and well-being company, and Allina Health are expanding their existing agreement to focus on value-based care for Humana’s Medicare Advantage members in

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer


Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the phase 3 pivotal LUNAR trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with immune

Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor: https://mms.businesswire.com/media/20200817005658/en/810396/5/deciphera-logo-color-RGB-TM_.jpg
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that the

Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Agehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age


Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas

Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that investigators presented results from the neratinib arm of the Phase II Individualized Screening Trial of

Quidel Presents at 33rd Annual Piper Sandler Healthcare Conference: https://mms.businesswire.com/media/20191114005606/en/588971/5/Quidel_Horiz_Sml_Vector_CMYK.jpg
Quidel Presents at 33rd Annual Piper Sandler Healthcare Conference


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it participated in a

Xencor to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present at Upcoming Investor Conferences


Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 9 abstracts that will be presented at the 2021 San Antonio Breast Cancer Symposium (SABCS), to be held

Simulations Plus Names Sharlene Evans to Board of Directors: https://mms.businesswire.com/media/20211119005238/en/1278208/5/SharleneEvans_highres.jpg
Simulations Plus Names Sharlene Evans to Board of Directors


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it

Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Olderhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a booster dose of the

Dr. Otis Brawley Named to Agilent Board of Directors: https://mms.businesswire.com/media/20211118005228/en/928541/5/Otis_Brawley_High_Res.jpg
Dr. Otis Brawley Named to Agilent Board of Directors


Agilent Technologies, Inc. (NYSE: A) today announced that Dr. Otis W. Brawley, a Bloomberg Distinguished Professor with the Department of Oncology and Epidemiology at the Johns Hopkins University

Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitishttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis


Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved XELJANZ® (tofacitinib) 5 mg twice daily for the treatment of adults with active ankylosing spondylitis (AS) who

Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it presented simulation

Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19


Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID™